ESMO 2016 Congress

Genitourinary Cancers

07 Oct - 11 Oct 2016, Copenhagen, Denmark

ESMO-Congress-2016-square

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Find the abstracts, posters, PDF presentation and webcasts from ESMO 2016 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Back-to-the-basics

Date: 07 Oct 2016
Presenter: Sjoerd van der Burg
Resources: Presentation, Webcast
Topics: Basic Science, Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...-checkpoints-Do-we-really-know-how-they-work

Date: 07 Oct 2016
Presenter: Ignacio Melero
Resources: Presentation, Webcast
Topic: Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/T-cell-therapy-For-whom-and-when2

Date: 07 Oct 2016
Presenter: Inge-Marie Svane
Resources: Presentation, Webcast
Topic: Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Welcome-to-Copenhagen

Date: 07 Oct 2016
Presenter: Ulrik Lassen
Resources: Webcast

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/ESMO-2016-Scientific-address

Date: 07 Oct 2016
Presenter: Andrés Cervantes
Resources: Presentation

https://oncologypro.esmo.org/Meeting-Resour...the-clinical-benefit-of-antineoplastic-drugs

Date: 07 Oct 2016
Presenter: Alberto Sobrero
Resources: Presentation

https://oncologypro.esmo.org/Meeting-Resour...2016/ESMO-Lifetime-Achievement-Award-lecture

Date: 07 Oct 2016
Presenter: Richard Peto
Resources: Presentation

https://oncologypro.esmo.org/Meeting-Resour...line-therapy-for-small-cell-lung-cancer-SCLC

BackgroundAlisertib, a selective AAK inhibitor, showed single-agent antitumor activity in preclinical in vivo SCLC models and was synergistic with P in this setting. We report the efficacy (PFS, OS, ORR) and safety from this study.

Date: 07 Oct 2016
Presenter: Taofeek Owonikoko
Resources: Abstract, Presentation, Webcast
Topic: Small-Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour...usions-responding-to-aurora-kinase-inhibitor

BackgroundAlthough there is a high ORR to platin/etoposide, small cell lung carcinoma (SCLC) patients inevitably recur, and second line topotecan has only a 20% ORR.

Date: 07 Oct 2016
Presenter: Siraj Ali
Resources: Abstract
Topic: Small-Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour...Invited-discussant-abstracts-1423O-and-1424O

Date: 07 Oct 2016
Presenter: Pilar Garrido Lopez
Resources: Presentation, Webcast
Topic: Lung and other Thoracic Tumours